{"version":"1.0","type":"link","title":"Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial.","author_name":"Lu S 외","author_url":"https://prs-insight.online/author/Lu%20S","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/98336","thumbnail_width":1200,"thumbnail_height":630}